Articles written by: Eddie Ferreira

Apple Com (AAPL) Shareholder Lucas Capital Management Has Lowered Position; Puzo Michael J Has Raised Its 3M (MMM) Holding by $568,260

Apple Com (AAPL) Shareholder Lucas Capital Management Has Lowered Position; Puzo Michael J Has Raised Its 3M (MMM) Holding by $568,260

Lucas Capital Management decreased its stake in Apple Inc Com (AAPL) by 4.94% based on its latest 2018Q3 regulatory filing with the SEC. Lucas Capital Management sold 1,629 shares as the company’s stock declined 22.32% with the market. The hedge fund held 31,341 shares of the computer manufacturing company at […]

Reviewing Western Asset Mortgage Defined Opportunity Fund Inc. (DMO)’s and U.S. Global Investors Inc. (NASDAQ:GROW)’s results

Western Asset Mortgage Defined Opportunity Fund Inc. (NYSE:DMO) and U.S. Global Investors Inc. (NASDAQ:GROW) compete with each other in the Asset Management sector. We will analyze and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per […]

Actavis Plc: Orexigen Therapeutics, Inc. And Takeda Pharmaceutical File Lawsuit To Block Generic Weight-Loss Pill

Actavis Plc: Orexigen Therapeutics, Inc. And Takeda Pharmaceutical File Lawsuit To Block Generic Weight-Loss Pill

Orexigen Therapeutics, Inc. (NASDAQ:OREX) and its partner Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) have filed a lawsuit against Actavis Plc (NYSE:ACT) to block a generic version of a weight-loss pill sold in the market under the name Contrave, according to Reuters. The lawsuit against Actavis Laboratories FL Inc, Andrx Corp, […]

Comparison of Merrimack Pharmaceuticals Inc. (MACK) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

As Biotechnology companies, Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Merrimack Pharmaceuticals Inc. N/A […]

$1.76 EPS Expected for Genmab A/S (GNMSF); Brookfield Infrastructure Partners L.P. (BIP) Had 2 Bullish Analysts

$1.76 EPS Expected for Genmab A/S (GNMSF); Brookfield Infrastructure Partners L.P. (BIP) Had 2 Bullish Analysts

Among 3 analysts covering Brookfield Infrastructure (NYSE:BIP), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Brookfield Infrastructure had 4 analyst reports since August 27, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Citigroup on Thursday, November 29. The company was maintained on Monday, […]